ELIMINATION OF ANTIPYRINE AND ITS METABOLITES IN INTERFERON-TREATED HEPATITIS-C

被引:4
|
作者
SIECK, JO
ELYAZIGI, A
ALI, H
DOSSING, M
SAOUR, J
RAINES, DA
ERNST, P
机构
[1] BISPEBJERG HOSP,DEPT MED P,DK-2400 COPENHAGEN,DENMARK
[2] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT MED,RIYADH 11211,SAUDI ARABIA
[3] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT BIOL & MED RES,RIYADH 11211,SAUDI ARABIA
[4] KING FAISAL SPECIALIST HOSP & RES CTR,DEPT ONCOL,RIYADH 11211,SAUDI ARABIA
来源
HUMAN & EXPERIMENTAL TOXICOLOGY | 1994年 / 13卷 / 09期
关键词
D O I
10.1177/096032719401300902
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
1 To study the effect of interferon on hepatic drug metabolism in chronic hepatitis C, we examined nine patients before and at the end of 6 months of interferon treatment. 2 Routine liver function was determined together with the salivary clearance of antipyrine and the 48 h urinary excretion of the main metabolites of antipyrine: 4-hydroxyantipyrine 3-hydroxymethylantipyrine and norantipyrine before and after 6 months of interferon treatment. 3 Liver pathology, routine liver function, and antipyrine metabolism remained unchanged after patients were treated for 6 months with interferon for a histologically advanced but clinically compensated chronic hepatitis C. ,
引用
收藏
页码:598 / 601
页数:4
相关论文
共 50 条
  • [1] PREDICTIVE VALUE OF HEPATITIS-C VIRUS DENSITY ANALYSIS FOR RELAPSE IN INTERFERON-TREATED CHRONIC HEPATITIS-C PATIENTS
    KANTO, T
    HAYASHI, N
    TAKEHARA, T
    HAGIWARA, H
    MITA, E
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    HEPATOLOGY, 1994, 20 (04) : A157 - A157
  • [3] ANTIPYRINE CLEARANCE AND RESPONSE TO INTERFERON TREATMENT IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS-C
    COVERDALE, SA
    BYTHE, K
    FIELD, J
    FARRELL, GC
    HEPATOLOGY, 1993, 18 (04) : A228 - A228
  • [4] ANTIPYRINE CLEARANCE AND RESPONSE TO INTERFERON TREATMENT IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS-C
    COVERDALE, S
    BYTH, K
    FIELD, J
    LIDDLE, C
    LIN, R
    FARRELL, GC
    HEPATOLOGY, 1995, 22 (04) : 1065 - 1071
  • [5] Diabetes Enhances Hepatocarcinogenesis in Noncirrhotic, Interferon-treated Hepatitis C Patients
    Kawamura, Yusuke
    Arase, Yasuji
    Ikeda, Kenji
    Hirakawa, Miharu
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Saitoh, Satoshi
    Yatsuji, Hiromi
    Sezaki, Hitomi
    Akuta, Norio
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Kumada, Hiromitsu
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 (10): : 951 - U1700
  • [6] Long-term course of interferon-treated chronic hepatitis C
    Cammà, C
    Di Marco, V
    Lo Iacono, O
    Almasio, P
    Giunta, M
    Fuschi, P
    Vaccaro, A
    Fabiano, C
    Magrin, S
    Di Stefano, R
    Bonura, C
    Pagliaro, L
    Craxì, A
    JOURNAL OF HEPATOLOGY, 1998, 28 (04) : 531 - 537
  • [7] HEPATITIS-C TREATED WITH INTERFERON IN RENAL-TRANSPLANTS
    DELCERRO, LAJ
    GRINO, E
    NEFROLOGIA, 1992, 12 (03): : 276 - 277
  • [8] Hepatocellular carcinoma in sustained responders of interferon-treated chronic hepatitis C
    Okanoue, T
    Itoh, Y
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (02) : 121 - 123
  • [9] INTERFERON AND HEPATITIS-C
    TERRAULT, N
    WRIGHT, T
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (22): : 1509 - 1511
  • [10] DECREASE OF HEPATITIS-C VIRUS-RNA IN THE LIVER OF PATIENTS WITH CHRONIC HEPATITIS-C TREATED WITH INTERFERON
    MATSUMOTO, M
    FUJIMORI, K
    OKUNO, T
    TAKEDA, M
    SHINDO, M
    ARAI, K
    OKANOUE, T
    KASHIMA, K
    SOKAWA, Y
    HEPATOLOGY, 1991, 14 (04) : A74 - A74